$MOH (Molina Healthcare, Inc.)

$MOH {{ '2016-08-03T11:15:32+0000' | timeago}} • Announcement

$MOH expects the $AET/$HUM asset acquisition to add to its earnings upon closing. Company expects to fund the deal with available cash, but has also received a debt commitment letter from Barclays in support of its financing obligations under the agreements.

$DGX {{ '2017-10-18T21:05:30+0000' | timeago}} • Announcement

Medical diagnostic company $DGX has agreed to acquire Cleveland HeartLab from equity investors. The company intends to set up a national center of excellence in diagnostic information services at Cleveland HeartLab's laboratory. The all-equity transaction is expected to close in 4Q17. The financial details of the deal were not disclosed.

$LLY {{ '2017-10-18T18:15:06+0000' | timeago}} • Announcement

$LLY inks a deal with Germany-based CureVac to develop and market up to 5 cancer vaccines. Lilly would pay CureVac $50MM as upfront fee and make an equity investment of EUR45MM. If successful, CureVac would receive more than $1.7Bil as milestone payment. Subject to the closing, Lilly expects to incur a charge of $0.03 per share to its earnings.

$UNH {{ '2017-10-18T15:11:12+0000' | timeago}} • Webcast

$UNH's health services business Optum seems to be on a roll. Optum's third quarter revenues eclipsed 8.4% to $23Bil, which is nearly half of $UNH’s total revenues. All business segments of Optum have generated double-digit earnings growth in 3Q. OptumHealth now directly reaches 90MM US consumers, which is an increase of 9MM vs. last year.

$CVS {{ '2017-10-18T15:07:12+0000' | timeago}} • Announcement

$CVS signed a five-year agreement with $ANTM to provide services to support  IngenioRx, effective Jan 1, 2020. Based on this CVS Caremark will manage certain services for IngenioRx.

$UNH {{ '2017-10-17T19:30:35+0000' | timeago}} • Announcement

$UNH is the first firm amongst its peers to report earnings every quarter. For the first time in its history, it is on track to cross revenues of $200Bil in 2017. 3Q revenues jumped 9% to $50.3Bil. $UNH's withdrawal from ACA individual insurance markets, along with a health insurance tax deferral, reduced revenues by $1.6Bil and growth rate by 4%.

$HUM {{ '2017-10-17T18:30:27+0000' | timeago}} • Announcement

$HUM unit Humana Foundation has appointed Walter D Woods as CEO. Previously, Woods served as president of the Evangelical Lutheran Good Samaritan Foundation. He joined the Foundation after holding various executive-level roles in organizations such as AARP Foundation, World Bank and Boys & Girls Clubs.

$UNH {{ '2017-10-17T17:16:02+0000' | timeago}} • Announcement

$UNH reported 26% jump in its profits aided by strong growth in its Optum business. This is the first quarter the health insurer is reporting results under the helm of new CEO Dave Wichmann, who replaced Steve Hemsley in September. The company also raised its outlook for 2017. It now expects GAAP EPS to touch $9.45 and adjusted EPS to reach $10.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$UNH {{ '2017-10-17T11:55:37+0000' | timeago}} • Infographic

$UNH UnitedHealth Earnings AlphaGraphics: Q3 2017 Highlights

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$LLY {{ '2017-10-16T19:27:03+0000' | timeago}} • Announcement

The BoD of $LLY declared a dividend for 4Q17 of $0.52 per share, payable on Dec. 8, 2017 to shareholders as of Nov. 15, 2017.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$HUM {{ '2017-10-12T22:12:06+0000' | timeago}} • Announcement

$HUM is expanding its existing relationship with TruHearing, a hearing health care company, to include hearing care and hearing aid benefits within more of its Medicare Advantage plan offerings. $HUM is including this hearing benefit on certain 2018 Medicare Advantage plans, which will be offered in 34 states.

$ANTM {{ '2017-10-12T15:09:20+0000' | timeago}} • Announcement

$ANTM's local affiliate has entered into a build-to-suit agreement with Portman Holdings for the custom development of about 352,000 square-foot building located in the heart of Midtown Atlanta, which is already home to Anthem’s Innovation Studio. Construction is planned to begin in January 2018 with an expected completion in two years.

$LLY {{ '2017-10-12T14:50:24+0000' | timeago}} • Announcement

FDA grants priority review for $LLY's breast cancer drug Verzenio, which was approved by the agency on Sept. 28. 2017. Now, FDA will speed up the review and will take action within eight months.  On Oct. 10, 2017, Lilly announced that Verzenio failed in the Phase 3 study for treating advanced lung cancer.

$DXC {{ '2017-10-12T12:50:44+0000' | timeago}} • Announcement

$DXC has decided to combine its US Public Sector business with Vencore Holding and KeyPoint Government Solutions to form an independent publicly traded company to serve US public sector clients. Formation of the new entity is expected to complete in March 2018. The proceeds from the transaction will be used to reduce debt and repurchase shares.

$MCK {{ '2017-10-11T18:31:37+0000' | timeago}} • Announcement

Biologics, a $MCK Specialty Health oncology pharmacy services company, has been selected by $LLY to be in the limited distribution network for Verzenio (abemaciclib), $LLY's first oral oncolytic indicated for metastatic breast cancer. Verzenio obstructs growth of cancer cells by specifically blocking cyclin-dependent kinases, CDK4 and CDK6.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$LLY {{ '2017-10-10T13:44:54+0000' | timeago}} • Announcement

$LLY's advanced lung cancer treatment drug Verzenio flunks in meeting the end goal of overall survival among the 453 patients in the Phase 3 JUNIPER trial study. The most common adverse events experienced by these patients were diarrhea, fatigue, decreased appetite, and nausea. Last month, FDA approved Verzenio for the treatment of breast cancer.

$DXC {{ '2017-10-10T13:25:42+0000' | timeago}} • Announcement

$DXC agreed to buy Logicalis SMC, one of the Netherlands' provider of technology-enabled solutions for the service management sector. The combination of Logicalis SMC with $DXC's Fruition Partners' business solidifies $DXC's position as one of the most experienced global integrators for $NOW, a $DXC strategic partner.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
ENZ (Enzo Biochem Inc.)
Thursday, September 28 2017 - 12:30pm
PDCO (Patterson Companies, Inc.)
Thursday, August 24 2017 - 2:00pm
DXC (DXC Technology Company)
Tuesday, August 8 2017 - 9:00pm
GTS (Triple-S Management Corporation)
Tuesday, August 8 2017 - 1:00pm
WCG (WellCare Health Plans, Inc.)
Friday, August 4 2017 - 1:00pm
CI (Cigna Corp.)
Friday, August 4 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
AET (Aetna Inc.)
Thursday, August 3 2017 - 12:30pm
MOH (Molina Healthcare, Inc.)
Wednesday, August 2 2017 - 9:00pm
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
HUM (Humana Inc.)
Wednesday, August 2 2017 - 1:00pm
ZIOP (ZIOPHARM Oncology, Inc.)
Monday, July 31 2017 - 8:30pm
ACHC (Acadia Healthcare Company, Inc.)
Friday, July 28 2017 - 1:00pm
MGLN (Magellan Health, Inc.)
Friday, July 28 2017 - 12:30pm
LH (Laboratory Corp. of America Holdings)
Wednesday, July 26 2017 - 1:00pm
ANTM (Anthem, Inc.)
Wednesday, July 26 2017 - 12:30pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
CNC (Centene Corp.)
Tuesday, July 25 2017 - 12:30pm

AlphaGraphics you may like